ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
HitGen, a biotech company based in China with labs in Houston, will work with Scripps Research Institute and its affiliate, the California Institute for Biomedical Research (Calibr). The partners will use HitGen’s DNA-encoded small-molecule libraries to discover and develop oncology, regenerative medicine, and virology drugs. Scripps and Calibr will provide target materials and expertise. The alliance comes just one week after HitGen entered a multiyear drug discovery deal with Pfizer
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter